Laboratory biomarkers associated with COVID-19 severity and management

S Keddie, O Ziff, M K L Chou, R L Taylor, A Heslegrave, E Garr, N Lakdawala, A Church, D Ludwig, J Manson, M Scully, E Nastouli, M D Chapman, M Hart, M P Lunn, S Keddie, O Ziff, M K L Chou, R L Taylor, A Heslegrave, E Garr, N Lakdawala, A Church, D Ludwig, J Manson, M Scully, E Nastouli, M D Chapman, M Hart, M P Lunn

Abstract

The heterogeneous disease course of COVID-19 is unpredictable, ranging from mild self-limiting symptoms to cytokine storms, acute respiratory distress syndrome (ARDS), multi-organ failure and death. Identification of high-risk cases will enable appropriate intervention and escalation. This study investigates the routine laboratory tests and cytokines implicated in COVID-19 for their potential application as biomarkers of disease severity, respiratory failure and need of higher-level care. From analysis of 203 samples, CRP, IL-6, IL-10 and LDH were most strongly correlated with the WHO ordinal scale of illness severity, the fraction of inspired oxygen delivery, radiological evidence of ARDS and level of respiratory support (p ≤ 0.001). IL-6 levels of ≥3.27 pg/ml provide a sensitivity of 0.87 and specificity of 0.64 for a requirement of ventilation, and a CRP of ≥37 mg/l of 0.91 and 0.66. Reliable stratification of high-risk cases has significant implications on patient triage, resource management and potentially the initiation of novel therapies in severe patients.

Keywords: Biomarkers; COVID-19; CRP; Cytokines; IL-10; IL-6; Intensive care; LDH.

Conflict of interest statement

None.

Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
Heatmap of biochemical markers and their association with COVID-19 illness severity. Heatmap shows biochemical signatures for each patient, arranged by WHO COVID-19 severity score. Visualisation was performed using the pheatmap R package. Biomarkers values are log10 transformed, centred and scaled. No patients had WHO severity scores 0, 1 or 2 as these are non-hospitalised patients. A score of 3 is hospitalised patients requiring no oxygen therapy; a score of 4 requires oxygen therapy; 5 requires non-invasive ventilation (NIV); of 6 requires intubation and mechanical ventilation; and 7 requires ventilation and additional organ support including vasopressors, renal replacement therapy and ECMO. A score of 8 is death. Higher levels of CRP, IL-6, IL-10 LDH and TNF-α are associated with higher WHO COVID-19 severity scores.
Fig. 2
Fig. 2
CRP, IL-6, IL-10, LDH and TNF- α levels predict the requirement for mechanical ventilation and intensive care. A) Split by four categories of respiratory support (none; supplemental oxygen; continuous positive airway pressure (CPAP); and mechanical ventilation. One way ANOVA shows these four categories are significantly different for CRP, IL-6, IL-10, LDH and TNF- α. B) Receiver operator characteristic curves of CRP, IL-6, IL-10, LDH and TNF- α demonstrating the area under the curve (AUC) for predicting the requirement for intensive care.

References

    1. McGonagle D., Sharif K., O’Regan A., Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev. 2020;19(6):102537.
    1. ICNARC . 2020. ICNARC Report on COVID-19 in Critical Care. London.
    1. European center for disease prevention and control . 2020. Rapid Risk Assessment - Coronavirus Disease 2019 COVID-19 in the EU/EEA and the UK – Eighth Update.
    1. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
    1. Herold T., Jurinovic V., Arnreich C., et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. Jul 2020;146(1):128–136. doi: 10.1016/j.jaci.2020.05.008. (2020.04.01.20047381)
    1. Coomes E.A., Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Rev Med Virol. Aug 2020;26(e2141) (2020.03.30.20048058)
    1. European center for disease prevention and control . 2020. Case Definition for Coronavirus Disease 2019 (COVID-19), as of 29 May 2020.
    1. World Health Organisation . 2020. Blueprint Novel Coronavirus COVID-19 Therapeutic Trial Synopsis.
    1. Williamson E.J., Walker A.J., Bhaskaran K., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. Aug 2020;584(7281):430–436. doi: 10.1038/s41586-020-2521-4.
    1. World Health Organisation . 2020. Coronavirus Disease (COVID-19) Situation Reports.
    1. Liu F., Li L., Xu M., et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J. Clin. Virol. 2020;127
    1. Chen X., Zhao B., Qu Y., et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin. Infect. Dis. Apr 2020;17(449) doi: 10.1093/cid/ciaa449.
    1. Lagunas-Rangel F.A., Chávez-Valencia V. High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patients. J. Med. Virol. April 2020;16(10) doi: 10.1002/jmv.25900.
    1. Maes B., Bosteels C., De Leeuw E., et al. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):468.
    1. Rilinger J., Kern W.V., Duerschmied D., et al. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):470.
    1. Wan S., Yi Q., Fan S., et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br. J. Haematol. 2020;189(3)
    1. L C., HG L., W L., et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin. J. Tuberc Respir. Dis. 2020;43(0)
    1. Huet T., Beaussier H., Voisin O., et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. Jul 2020;2(7):e393–e400.
    1. Balcioglu Y.H., Yesilkaya U.H., Gokcay H., Kirlioglu S.S. May the central nervous system be fogged by the cytokine storm in COVID-19?: an appraisal. J. NeuroImmune Pharmacol. 2020;15(3):343–344.
    1. Huang W., Berube J., McNamara M., et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytom Part A. 2020;97(8):772–776.
    1. He R., Lu Z., Zhang L., et al. The clinical course and its correlated immune status in COVID-19 pneumonia. J. Clin. Virol. 2020;127

Source: PubMed

3
Prenumerera